1,000 species get their genomes sequenced for the first time
A thousand reference genomes of the highest quality have now been produced for diverse eukaryotic species across the tree of life.
Mosaic’s becoming
The Sanger Institute is committed to innovative science at scale, but we need partners and investors to transfer this science into the clinic. Mariya Chhatriwala, Business Development Manager, gives us her insights on how the Sanger Institute’s fifth spin-out company came to be.
Behind the Heart Cell Atlas
Histologists, cardiologists, immunologists, cell biologists, software developers, bioinformaticians and specialist technicians have worked together to see individual cells in unprecedented detail. Using spatial genomics, they located each cell to its precise location in the heart.
Swapping stethoscopes for sequencing – a doctor’s journey
Chenqu Suo looks back on her PhD, discussing her scientific highlights and her thoughts about what makes the Sanger Institute a special place to study.
New postdoc award scheme winners
Meet the first two winners of our new internal funding scheme to accelerate postdocs along their career trajectory
To influenza and beyond
The Sanger Institute’s new Respiratory Virus and Microbiome Initiative will lead the way in developing the genomic tools and methodology to study and track a range of viruses and understand how they interact with the respiratory microbiome and human hosts.
Software to sort samples and sequence species at scale
Meet the software developers, informaticians and bioinformaticians who are helping to sequence the DNA of all life on earth.
Understand, predict, engineer
Ben Lehner joins the Sanger Institute as a new Senior Group Leader. He seeks to lay the foundations for programmable biology.
From genomes to medicines: an interview with Ian Dunham
Ian Dunham has been a pillar of Open Targets since its inception. Helena Cornu sat down with him to understand how his career led him from the Human Genome Project to Director of Open Targets, and what he envisions for the future of the consortium.‌
